EGTX Share Price Performance
SEK 5.78
-0.07 (-1.20%)
Price SEK 5.78
Share PriceSEK 5.78
EGTX Community Narratives
There are no narratives available yet.
Recent EGTX News & Updates
No updates
Egetis Therapeutics AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 21, 2025
- Earnings per share (EPS)
- -0.92
- Gross Margin
- 60.17%
- Net Profit Margin
- -709.85%
- Debt/Equity Ratio
- 22.8%
Egetis Therapeutics AB (publ) Competitors
About EGTX
- Founded
- 2006
- Employees
- 38
- CEO
- WebsiteView website
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Swedish Market Performance
- 7 Days: 0.6%
- 3 Months: 3.8%
- 1 Year: 2.5%
- Year to Date: 0.7%
Over the last 7 days, the market has remained flat, although notably the Materials sector gained 3.1% in that time. As for the longer term, the market has also been flat over the past year. Looking forward, earnings are forecast to grow by 17% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading